Tag: Gene Therapy

MedImmune and 4D Molecular Therapeutics to collaborate on AAV gene therapy

gene-therapy
MedImmune, the global biologics research and development arm of AstraZeneca, and 4D Molecular Therapeutics announced a collaboration to develop and commercialize a gene therapeutic for patients with chronic lung disease.

BioNTech and Genevant Sciences entered into a mRNA therapy collaboration

gene-editing
BioNTech AG and Genevant Sciences announced that they have entered into a collaboration to develop five mRNA therapeutic programs for rare diseases with high unmet medical need.

BrainStorm Cell Therapeutics develops NurOwn: ALS therapy

chemistry
The first company has provided a potential out-of-pocket price for patients who seek access through the recently passed federal Right-to-Try legislation and it’s not cheap. BrainStorm Cell Therapeutics could charge more than $300,000 for its Phase III experimental amyotrophic lateral sclerosis therapy NurOwn.

Sarepta Therapeutics and Brammer Bio start a manufacturing cooperation

gene therapy
Sarepta Therapeutics, a biopharmaceutical company focused on the discovery and development of genetic medicine to treat rare neuromuscular diseases, entered into a long-term strategic manufacturing partnership with Brammer Bio.

Regenxbio receives $100 million license payment from Novartis

novartis
REGENXBIO announced that it has received an accelerated license payment of $100 million under its license agreement with AveXis, due to the acquisition of AveXis by Novartis.

BIOCAD will invest $26 million in infrastructure for gene therapies development

biocad
The agreements on collaboration and joint research in the area of adoptive immunotherapy were signed between V.A. Almazov National Medical Research Center and BIOCAD, a biotech company, on May 24, 2018.

Horizon 2020 provides EUR 3.6 million financing to CombiGene

gene-therapy
Horizon 2020, the EU framework programme for research and development, will invest 3.6 million euros in CombiGene’s ongoing development and commercialization of the company’s gene therapy project.

Belgian biotech Celyad received the required funding to keep up with CAR-T race

investments
Celyad (formerly known as Cardio3 BioSciences), a clinical-stage biopharmaceutical company focused on the identification and development of specialized cell based therapies, has raised €40.1 million in a global offering.

Vectalys and FlashCell formed a new gene therapy company

gene-therapy
Vectalys, a leading biotech company specialized in manufacturing lentiviral solutions, and FlashCell, a company developing non-integrating lentiviral delivered RNA therapeutics, merged to create Flash Therapeutics.

CGT Catapult officially launched its cell and gene therapy manufacturing centre

dna
Cell and Gene Therapy Catapult officially opened its unique cell and gene therapy manufacturing centre. Backed by investment from UK Government, the centre will support and develop the global cell and gene therapy industry.

The Government of India submitted a draft amendment on cell therapies

stem cells
The Ministry of Health and Family Welfare of India, after consultations with the Drugs Technical Advisory Board (DTAB), has proposed a draft amendment that defines stem cell-based products (SCBP).

GSK passes its portfolio of rare disease gene therapies to Orchard Therapeutics

gene therapy
GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard, securing the continued development of the programmes and access for patients.

Lonza launched its dedicated cell-and-gene-therapy facility in USA

lonza building
Lonza opened the world’s largest dedicated cell-and-gene-therapy facility, which was built in anticipation of the rising demand from developers of cell and gene therapies.

Novartis buys gene therapy company AveXis

novartis
Novartis announced that it has entered into an agreement and plan of merger with AveXis, Inc. to acquire the US-based clinical stage gene therapy company for $8.7 billion.

Oxford BioMedica intends to obtain financing for further expansion

research
Oxford BioMedica, a leading gene and cell therapy company, intends to raise approximately $28,4 million to fund the expansion of its bioprocessing facilities.

Gilead and Sangamo joined up for development of next gen cell therapies

gene-editing
Kite, a Gilead Company, and Sangamo Therapeutics entered into a worldwide collaboration using Sangamo’s zinc finger nuclease (ZFN) technology platform for the development of next-generation ex vivo cell therapies in oncology.